Get the Stockscreener App
2.44
1.61%
-0.04
After Hours:
2.43
-0.010
-0.41%
Oramed Pharmaceuticals Inc stock is traded at $2.44, with a volume of 102.94K.
It is down -1.61% in the last 24 hours and up +2.09% over the past month.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
See More
Previous Close:
$2.48
Open:
$2.47
24h Volume:
102.94K
Relative Volume:
0.99
Market Cap:
$100.29M
Revenue:
$2.70M
Net Income/Loss:
$5.53M
P/E Ratio:
-4.7843
EPS:
-0.51
Net Cash Flow:
$-10.55M
1W Performance:
+4.95%
1M Performance:
+2.09%
6M Performance:
-16.44%
1Y Performance:
-6.51%
1-Day Range:
$2.44
$2.54
1-Week Range:
$2.35
$2.55
52-Week Range:
$1.67
$3.67
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Name
Oramed Pharmaceuticals Inc
Sector
Industry
Phone
646-844-1164
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-20-21 | Initiated | Canaccord Genuity | Buy |
| Feb-09-21 | Initiated | National Securities | Buy |
| Dec-03-20 | Initiated | Alliance Global Partners | Buy |
| Mar-11-20 | Initiated | Aegis Capital | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-17 | Resumed | B. Riley FBR, Inc. | Buy |
| May-26-16 | Reiterated | FBR Capital | Outperform |
| Dec-01-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-19-15 | Initiated | FBR Capital | Outperform |
| Apr-13-15 | Resumed | MLV & Co | Buy |
| Jan-30-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Initiated | MLV & Co | Buy |
| Dec-03-13 | Initiated | Aegis Capital | Buy |
View All
Oramed Pharmaceuticals Inc Stock (ORMP) Latest News
Murchinson Ltd. Raises Position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - MarketBeat
Oramed signs $11.5 million deal for clinical trial services - Investing.com
Non-Alcoholic Steatohepatitis Pipeline Insights 2024: - openPR
Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded by StockNews.com to Hold - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) and Oramed Pharmaceuticals (NASDAQ:ORMP) Financial Review - Defense World
Murchinson Ltd. Trims Stock Holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - MarketBeat
Scilex Holding agrees to payment terms with Oramed Pharmaceuticals - Investing.com India
Scilex Holding agrees to payment terms with Oramed Pharmaceuticals - Investing.com
Oramed Pharmaceuticals (ORMP) Price Target Increased by 57.50% to 3.21 - MSN
Moors & Cabot Inc. Buys 164 Shares of O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
Oriole Resources (LON:ORR) Shares Down 2.3% - Defense World
Sidoti Csr Weighs in on Orion Group Holdings, Inc.’s Q3 2024 Earnings (NYSE:ORN) - Defense World
O'Reilly Automotive, Inc. (NASDAQ:ORLY) Position Raised by E Fund Management Co. Ltd. - MarketBeat
BMO Capital Markets analysts downgrades a Market perform rating for Ionis Pharmaceuticals Inc (IONS) - Knox Daily
Wealthspire Advisors LLC Buys 12 Shares of O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
OMIC’s Market Whiplash: -10.31% YTD Decline, 69.47% Rise in 30 Days - The InvestChronicle
Ashton Thomas Private Wealth LLC Takes Position in O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
O’Reilly Automotive, Inc. (NASDAQ:ORLY) Shares Purchased by Acadian Asset Management LLC - Defense World
Private Advisor Group LLC Has $2.56 Million Stake in O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
Research Analysts Set Expectations for Oramed Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:ORMP) - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded by StockNews.com to “Hold” - Defense World
Comprehensive Study of Oral Biologics Market 2024-2031 - openPR
Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded to "Hold" at StockNews.com - MarketBeat
Oramed Pharmaceuticals’ (ORMP) Neutral Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright maintains Neutral rating on Oramed amid ongoing NMPA review - Investing.com India
H.C. Wainwright maintains Neutral rating on Oramed amid ongoing NMPA review - Investing.com
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
H.C. Wainwright maintains Neutral rating on Oramed amid ongoing NMPA review - Investing.com Canada
H.C. Wainwright maintains Neutral rating on Oramed amid ongoing NMPA review - Investing.com UK
Brokers Offer Predictions for Oramed Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:ORMP) - MarketBeat
ORMP: Balance Sheet Strong, Potential Benefits of Investments, JVs, Buybacks - MSN
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by StockNews.com to Buy - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to Buy by StockNews.com - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Below Two Hundred Day Moving Average of $2.58 - MarketBeat
Future Scope of Oral Biologics Market Overall Study Report - openPR
Oramed Pharmaceuticals (FRA:OJU1) 3-Year EPS without NRI Gr - GuruFocus.com
Oramed Pharmaceuticals (FRA:OJU1) Net Income From Continuin - GuruFocus.com
ORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q2 2024 - InvestorPlace
Oramed Pharmaceuticals (FRA:OJU1) COGS-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
Oramed Pharmaceuticals (FRA:OJU1) GF Value Rank : 1 (As of Aug. 19, 2024) - GuruFocus.com
ORMP (Oramed Pharmaceuticals) Purchase Of Investment : $-105.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Oramed Pharmaceuticals (FRA:OJU1) Liabilities-to-Assets : 0.04 (As of Jun. 2024) - GuruFocus.com
Oramed Pharmaceuticals (FRA:OJU1) Cash Flow from Financing : €1.07 Mil (TTM As of Jun. 2024) - GuruFocus.com
Oramed Pharmaceuticals (FRA:OJU1) Revenue : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Oramed Pharmaceuticals (FRA:OJU1) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
Oramed Pharmaceuticals (FRA:OJU1) Enterprise Value : €-51.81 Mil (As of Aug. 18, 2024) - GuruFocus.com
Oramed Pharmaceuticals (FRA:OJU1) Growth Rank : 1 (As of Aug. 18, 2024) - GuruFocus.com
ORMP (Oramed Pharmaceuticals) EPS (Basic) : $0.51 (TTM As of Jun. 2024) - GuruFocus.com
ORMP (Oramed Pharmaceuticals) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
Oramed Pharmaceuticals (XTAE:ORMP) Cash Flow from Investing : ₪292.15 Mil (TTM As of Jun. 2024) - GuruFocus.com
Oramed Pharmaceuticals (FRA:OJU1) EPS without NRI : €0.47 (TTM As of Jun. 2024) - GuruFocus.com
Oramed Pharmaceuticals Inc Stock (ORMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):